10-K: LENSAR, Inc. Details Capital Stock Structure and Regulatory Compliance in 10-K Filing

LENSAR, Inc.'s 10-K filing provides a detailed overview of its capital stock, including common and preferred shares, and outlines key regulatory and corporate governance provisions.

Summary

• LENSAR, Inc.'s authorized capital stock consists of 150,000,000 shares of common stock and 10,000,000 shares of preferred stock.
• The company has one class of securities registered under Section 12 of the Securities Exchange Act of 1934: common stock.
• Holders of common stock are entitled to one vote per share and do not have cumulative voting rights.
• The board of directors is authorized to issue preferred stock in one or more series without stockholder approval.
• On May 18, 2023, LENSAR issued 20,000 shares of Series A Convertible Preferred Stock, each with a stated value of $1,000, initially convertible into 7,940,446 shares of common stock.
• Series A preferred shares rank senior to common stock regarding dividends and liquidation.
• Holders of Series A preferred shares are entitled to vote on an as-converted basis with the common stock.
• The Series A preferred shares are subject to automatic redemption for cash upon a Fundamental Transaction.
• The company is subject to Section 203 of the Delaware General Corporation Law, which restricts business combinations with interested stockholders for three years.
• The company's bylaws allow special stockholder meetings to be called only by the chairman of the board, the CEO, or the board itself.
• The company's certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting.
• The board of directors is divided into three classes, with directors serving three-year terms.
• Directors can only be removed for cause and with the approval of at least two-thirds of the voting power of outstanding shares.
• Stockholders are not entitled to cumulative voting in the election of directors.
• The Court of Chancery of the State of Delaware is the exclusive forum for certain legal actions related to the company.
• The federal district courts of the United States will be the exclusive forum for the resolution of any complaint asserting a cause of action against the Company or any director, officer, employee or agent of the Corporation and arising under the Securities Act of 1933, as amended.
• The company is subject to extensive regulation by the FDA and other authorities, including premarket clearance and approval requirements.
• The company's products are Class II medical devices subject to 510(k) clearance.
• The company's manufacturing sites are subject to periodic inspection by the FDA for compliance with the Quality System Regulation (QSR).
• The company is subject to the Foreign Corrupt Practices Act (FCPA) and other anti-corruption laws.
• The company's success depends on obtaining, maintaining, and protecting its intellectual property rights, including patents and trademarks.
• As of December 31, 2023, the company owned approximately 212 issued patents and 112 pending patent applications globally.
• The company's material registered and unregistered trademarks include LENSAR, ALLY Adaptive Cataract Treatment System, and INTELLIAXIS.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive aspects such as revenue growth and technological advancements, the company is still facing significant challenges, including ongoing losses, supply chain issues, and regulatory hurdles. The sentiment is neutral to slightly negative due to the financial losses and risks outlined.

Positives

• The company has a strong intellectual property portfolio with numerous patents and trademarks.
• The ALLY System has received FDA clearance and is being commercialized, indicating progress in product development.
• The company has a direct sales force in the U.S. and a network of international distributors.
• The company is actively seeking regulatory approvals and certifications in various international markets.
• The company has a proven management team and board of directors with deep industry experience.

Negatives

• The company is subject to extensive government regulation and oversight, which could lead to compliance issues.
• The company is subject to anti-takeover provisions, which could make it difficult for a third party to acquire the company.
• The company is subject to the credit risk of some of its customers, which could result in material losses.
• The company may be unable to accurately forecast customer demand and its inventory levels.
• The company may be unable to secure adequate coverage or reimbursement by government or other third-party payors for procedures using its products.

Risks

• The company's results could be adversely affected by economic uncertainty or deteriorations in economic conditions.
• The company expects to incur operating losses for the near-term future and may not achieve or sustain profitability.
• The commercial success of the ALLY System depends on additional regulatory clearances and market acceptance.
• Patients may not be willing to pay the price difference for advanced cataract procedures.
• The company's future capital needs are uncertain, and additional funds may not be available on acceptable terms.
• Disruptions in the supply or manufacture of systems could negatively affect operating results.
• The company faces significant competition from larger, more established companies.
• The company must address many international business risks to market its products outside the U.S.
• The company is subject to extensive government regulation and oversight, and failure to comply could harm its business.
• The company may not receive necessary clearances or approvals for future products or modifications to current products.
• The company's success depends on its ability to obtain, maintain, and protect its intellectual property rights.

Future Outlook

The company expects to continue to incur losses and operating cash outflows for the near-term future as it continues to build its commercial and clinical infrastructure and pursue further regulatory clearances of its ALLY System. The company expects selling, general and administrative expenses to increase from current levels to support the expansion efforts in the U.S. and internationally for the ALLY System.

Industry Context

The document highlights the competitive landscape of the medical device industry, particularly in the cataract surgery market, where LENSAR faces competition from large multinational companies and smaller, emerging players. The company's focus on innovation and its ALLY System are positioned as key differentiators in this competitive environment.

Comparison to Industry Standards

• The document mentions that LENSAR achieved a 12.2% market share in femtosecond laser-assisted cataract surgery in 2023, based on the 2023 Cataract Surgical Equipment Market Report.
• LENSAR's systems averaged 445 procedures per installed device in 2023, compared to the estimated industry average of 382 procedures per year per installed device, according to the 2023 Cataract Surgical Equipment Market Report.
• The document notes that approximately 83% of global patients receiving a standard cataract procedure do not have significant astigmatism addressed surgically, highlighting a market opportunity for LENSAR's advanced procedures.

Legal Proceedings

• The company is involved in a class action lawsuit, Schaper v. LENSAR, Inc., et al., alleging violations of Sections 14(a) and 20(a) of the Exchange Act, as well as Rule 14d-9 promulgated thereunder, and asserting claims challenging the adequacy of disclosures in the definitive proxy statement filed with the SEC on June 20, 2023.

Related Party Transactions

• The company entered into an international distribution agreement with a company owned by a current employee in India.

Stakeholder Impact

• Shareholders face risks related to potential dilution, market volatility, and the company's ability to achieve profitability.
• Employees may be affected by the company's financial performance and its ability to provide competitive compensation and benefits.
• Customers may be impacted by the company's ability to deliver products and services on a timely basis and at a reasonable cost.
• Suppliers may be affected by the company's ability to meet its contractual obligations and maintain a stable supply chain.
• Creditors may be affected by the company's ability to repay its debts and maintain a healthy financial position.

Next Steps

• The company plans to continue expanding its sales and marketing efforts in the U.S. and internationally.
• The company will continue to pursue regulatory clearances and certifications for the ALLY System in various international markets.
• The company will continue to develop its proprietary, next-generation femtosecond laser, the ALLY System.

Key Dates

Keywords

capital stock, preferred stock, common stock, regulatory compliance, medical devices, FDA, intellectual property, patents, trademarks, ALLY System, cataract surgery, corporate governance